Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00565721
Other study ID # GE-135-003
Secondary ID
Status Completed
Phase Phase 2
First received November 28, 2007
Last updated August 13, 2014
Start date November 2007
Est. completion date September 2012

Study information

Verified date August 2014
Source GE Healthcare
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This proof-of-concept study is designed to assess the ability of [18F]AH-111585 PET imaging to detect tumors and angiogenesis. Up to 30 evaluable subjects are planned to be included at up to 2 study centers in the US. Subjects are considered evaluable if they undergo administration of AH-111585 (18F) Injection, dynamic and static PET imaging, and tumor tissue acquisition. The targeted population is adult subjects at initial diagnosis or recurrence with tumors ≥2.5 cm in diameter who are scheduled to undergo resection or biopsy of the tumor as a result of routine clinical treatment. The tumors must belong to one of the following 5 types:

- High-grade glioma, including glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma

- Lung cancer, including small cell lung cancer and non-small cell lung cancer

- Head and neck (H&N) tumors, including laryngeal squamous cell carcinoma, well-differentiated thyroid and oral cavity carcinoma

- Sarcoma

- Melanoma

Safety will be assessed from the rates of adverse events, changes in vital signs, changes in electrocardiogram (ECG) parameters, changes in physical examination findings, and changes in clinical laboratory findings.

Efficacy will be assessed as the correlations between parameters derived from the PET images and the reference standards. The reference standards will be immunohistology for αvβ3 integrins and other biomarkers specific for oncology and angiogenesis and from the standard of care imaging.

Measures obtained from optional DCE-CT imaging may also be used to compare the uptake and retention of [18F]AH-111585 in tumors obtained from the dynamic PET to assess functional status of the vascular system of the tumor.


Other known NCT identifiers
  • NCT00923767

Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date September 2012
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Selection of Subjects: The targeted subject population is adult subjects at initial diagnosis or recurrence with tumours =2.5 cm in diameter who are scheduled to undergo resection or biopsy of the tumour as a result of routine clinical treatment.

General Inclusion Criteria for all Subjects:

- The subject is =18 years old.

- The subject has been diagnostically imaged and is suspected of having a primary or metastatic tumour lesion =2.5 cm of one of the following types: high-grade glioma, including glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, including small cell lung cancer and non-small cell lung cancer; H&N tumours, including laryngeal squamous cell carcinoma, and well-differentiated thyroid and oral cavity carcinoma; sarcoma; and melanoma.

- The subject is scheduled to undergo resection or biopsy of the =2.5 cm target tumour as a result of routine clinical treatment.

- The subject is scheduled to undergo or has received standard of care diagnostic imaging work-up (following the study centre's routine procedures), e.g. CT with or without contrast, MRI with or without contrast, bone scintigraphy, X-ray, or FDG-PET.

- Female subjects need to be either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post menopausal (cessation of menses for more than 1 year), or if of childbearing potential the results of a serum pregnancy test performed within 24 hours must be negative and with the result known before administration of AH-111585 (18F) Injection. Female subjects of reproductive potential should also employ an effective method of birth control. Barrier contraceptives must be used throughout the study in both sexes.

- The subject is able and willing to comply with study procedures, and signed and dated informed consent is obtained.

- The subject has a blood urea nitrogen value and serum creatinine value of =1.5 of the upper normal limit.

- The subject has a platelet count of >75,000 x 10^6/L.

- The subject has a haemoglobin value of >9 g/dL.

- The subject has a prothrombin time and an activated partial thromboplastin time and within normal limits.

- The subject has a clinically acceptable (as judged by the investigator) physical examination at screening and is capable of self-care, i.e. Eastern Cooperative Oncology Group performance status is 0 to 2, such that the subject has a high chance to complete the study.

- The subject has not received any anti-angiogenic agents (e.g. bevacizumab, sorafenib, sunitinib) within 10 days prior to PET imaging.

- The subject has had no open wounds within 10 days prior to study entry.

- The chosen target tumour is not within the liver.

Inclusion Criteria Specific for Subjects with High-grade Glioma:

- The subject is suspected of having supratentorial malignant primary glioma (by biopsy or presenting MRI characteristics as determined by the subject's clinician) requiring further surgical resection as part of the recommended treatment plan for their newly diagnosed disease. These gliomas include glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma.

- The subject has undergone recent biopsy of newly diagnosed high-grade glioma, has recovered from the effects of surgical biopsy, and baseline on-study MRI/CT is performed within 14 days of entry into the study.

Exclusion Criteria:

- The subject is lactating.

- The subject is being treated with heparin or coumadin.

- The subject has received another investigational medicinal product (IMP) within 14 days before, or will receive an IMP within 1 week after administration of AH-111585 (18F) Injection.

- The subject was previously included in this study.

- The subject experienced substantial changes in their medical status before all essential study procedures (including all imaging procedures and surgical excision or biopsy) are performed.

- The subject has any contraindication to any of the study procedures, products used or its constituents (e.g. X-ray contrast media).

- The subject has known hyper- or hypo-coagulation syndromes. Such coagulopathies include but are not limited to Von Willebrand disease, Protein C deficiency, Protein S deficiency, Hemophilia A/B/C, Factor-V Leiden, and Bernard-Soulier syndrome.

- The subject is unable to lie down for 125 minutes.

- The subject suffers from claustrophobia.

- The subject has known diagnosis of human immunodeficiency virus (HIV) infection.

- The subject has known diagnosis of hepatitis B or C infection.

- The subject has known diagnosis of mental incapacitation and it affects their ability to consent.

- The subject has been diagnosed with a primary or metastatic tumour lesion <2.5 cm.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Drug:
Fluciclatide Injection - (AH111585 (F18))
18F labelled Cyclic RGD peptide PET agent for injection.

Locations

Country Name City State
United States GE Healthcare Office Princeton New Jersey

Sponsors (1)

Lead Sponsor Collaborator
GE Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß3 (Beta-3 Integrin) Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak and avß3 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. 0.22 and 0.24 equals a weak positive correlation and 0.16 and 0.18 equals a negligible correlation.
Three (3) of the 22 subjects did not have any avß3 integrin results. Ki-inp-Patlak is a graphical analysis technique based on the compartment model that uses linear regression to identify and analyze pharmacokinetics of tracers involving irreversible uptake.
Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Primary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß3 Integrin Expression in Tumors. (Correlation Between VT_inp-Logan and avß3 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively.
The Logan plot is the counterpart of the Patlak plot for reversible radiotracers.
Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Primary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß3 (Beta-3 Integrin) Integrin Expression in Tumors. (Correlation Between SUVw_55 and avß3 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively.
SUVw_55 is the standard uptake value at 55 minutes post-injection, normalized to weight.
Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Primary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß3 (Beta-3 Integrin) Integrin Expression in Tumors. (Correlation Between SUVR_55_blood and avß3 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
Twelve (12) of the 22 subjects had renal cell carcinoma (RCC) the remaining subjects did not have RCC.
SUVR_55_blood is the standard uptake value ratio (tumor-to-blood) at 55 minutes post-injection.
Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Primary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß3 Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak and avß3 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Primary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß3 Integrin Expression in Tumors. (Correlation Between VT_inp-Logan and avß3 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Primary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß3 Integrin Expression in Tumors. (Correlation Between SUVw_55 and avß3 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Primary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß3 Integrin Expression in Tumors. (Correlation Between SUVR_55_blood and avß3 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Secondary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß5 Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak avß5 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. 0.60 to 0.44 equals a moderately positive correlation and 0.33 to 0.37 equals a weak positive correlation.
Two (2) of the 22 subjects did not have any avß5 integrin results.
Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Secondary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß5 Integrin Expression in Tumors. (Correlation Between VT_inp-Logan and avß5 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Secondary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß5 Integrin Expression in Tumors. (Correlation Between SUVw_55 and avß5 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Secondary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß5 Integrin Expression in Tumors. (Correlation Between SUVR_55_blood and avß5 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Secondary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß5 Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak and avß5 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Secondary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß5 Integrin Expression in Tumors. (Correlation Between VT_inp-Logan and avß5 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Secondary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß5 Integrin Expression in Tumors. (Correlation Between SUVw_55 and avß5 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
Secondary Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of avß5 Integrin Expression in Tumors. (Correlation Between SUVR_55_blood and avß5 Optical Density) Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Tissue sample acquisition within 2 weeks of Fluciclatide PET scan. No
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk